Welcome
Welcome to the Alzheimer's Disease Drug Development Pipeline (AlzPipeline). AlzPipeline is also known as the Clinical Trial Observatory that monitors and analyzes the latest Alzheimer's Disease clinical trials. AlzPipeline is updated in real time with advanced data management tools to provide quantitative information on clinical trials and pipeline drugs.
Our Goal
Our goal is to provide information to help those developing new therapies for Alzheimer's disease and other neurodegenerative disorders to design their trials. We derive information from clinicaltrials.gov regarding clinical trial design, outcome measures, biomarkers, trial populations, trial duration, and other key elements.
We provide access to the database through tables, interactive figures, and other unique data visualization approaches. We provide answers to frequently asked questions, and we seek your feedback through our comment connections.
Who We Are
AlzPipeline is led by Dr. Jeffrey Cummings and Dr. Feixiong Cheng. We are funded by a National Institute on Aging Leadership Award to Dr. Cummings.
Jeffrey L. Cummings, MD, ScD (HC) is the Joy Chambers-Grundy Professor of Brain Sciences and Director of the Chambers-Grundy Center for Transformative Neuroscience, University of Nevada Las Vegas (UNLV). Dr. Cummings and his team provide insights into the pharmacologic characterization and mechanisms of action of the drugs in the Alzheimer's Disease and Related Disorders (ADRD) drug development pipeline.
Feixiong Cheng, PhD directs the Alzheimer's Network Medicine Laboratory of the Genomic Medicine Institute, Cleveland Clinic. Dr. Cheng and his team provide state-of-the-art database construction, management, interrogation as well as data visualization.
Future Directions
Drug development is an exciting enterprise that is constantly integrating new information regarding disease biology, pharmacology, clinical trial design, clinical outcomes, and biomarkers to assess emerging candidate therapies. The Clinical Trial Observatory captures these dynamic changes providing information to assess their utility in accelerating trials and improving the efficiency of drug development.
Plans for the Clinical Trial Observatory:
Add trial characteristics for devices being developed for treatment of Alzheimer's disease
Add cell therapies being advanced for treatment of Alzheimer's disease
Add gene therapies progressing through the Alzheimer's disease development pipeline
Expand the Clinical Trial Observatory to include information on other neurodegenerative disorders
Learn from users what information would be most valuable to them to assist in drug development
Publications
Alzheimer's disease drug development pipeline: 2023 Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2023;9:e12385. PubMed | PMC
Alzheimer's disease drug development pipeline: 2022 Cummings J, Lee G, Nahed P, Kambar ME, Zhong K, Fonseca J, Taghva K Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2022;8:e12295. PubMed | PMC
Alzheimer's disease drug development pipeline: 2021 Cummings J, Lee G, Zhong K, Fonseca J, Taghva K Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2021;7:e12179. PubMed | PMC
Alzheimer's disease drug development pipeline: 2020 Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2020;6:e12050. PubMed | PMC
Alzheimer's disease drug development pipeline: 2019 Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2019;5:272-293. PubMed | PMC
Alzheimer's disease drug development pipeline: 2018 Cummings J, Lee G, Ritter A, Zhong K Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2018;4:195-214. PubMed | PMC
Alzheimer's disease drug development pipeline: 2017 Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2017;3:367-384. PubMed | PMC
Alzheimer's drug-development pipeline: 2016 Cummings J, Mortsdorf T, Lee G Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2016;2:222-232. PubMed | PMC